Recently there has been a lot of progress toward improving outcomes for men with high-risk and very high-risk non-metastatic prostate cancer. In the past two decades, landmark studies have been published to support the use of brachytherapy boost, long-term hormonal therapy, chemotherapy, stereotactic body radiation therapy, surgical approaches, and postoperative radiation therapy. Recent results from the ASCENDE-RT trial suggest that brachytherapy boost substantially improves rates of biochemical failure-free survival and PSA nadir < 0.2 ng/mL, but with an increased risk of urinary morbidity. Other studies have suggested that prostatectomy, with potential postoperative radiation therapy based upon pathologic features or rising PSA level, may increase cure rates compared to other treatment options.
In this special issue, we welcome contributions on the subject of local therapy for high-risk prostate cancer. Submissions may address a broad variety of subjects, ranging from technical aspects of local therapies to clinical outcomes, health services research and cost considerations. The aim of this collection is to provide an updated perspective on a range of local therapies for high-risk and very high-risk prostate cancer, including surgical, radiotherapeutic and other approaches. Contributions that focus on regional nodal management, including for node-positive cancers, will also be considered. In addition to an emphasis on original research contributions, we welcome review articles.
We welcome contributions focusing on the following subject areas:
1. PET imaging for staging and target delineation in high-risk prostate cancer
2. Genomics for risk stratification and treatment decisions
3. Therapy approaches including Stereotactic Body Radiation Therapy (SBRT), HDR brachytherapy, combination therapy, and next-generation systemic therapy approaches (e.g. PARPi, Abi/Apa)
4. Neoadjuvant therapy options prior to prostatectomy including radiation therapy, androgen deprivation therapy, and chemotherapy
5. Urologists and Radiation Oncologists perspective on the benefits and drawbacks of prostatectomy for high-risk prostate cancer
6. Optimal timing of postoperative radiation therapy
7. Nodal treatment
Please contact the Guest Editors for discussion of your proposed manuscript prior to submission to avoid duplicative efforts.
Recently there has been a lot of progress toward improving outcomes for men with high-risk and very high-risk non-metastatic prostate cancer. In the past two decades, landmark studies have been published to support the use of brachytherapy boost, long-term hormonal therapy, chemotherapy, stereotactic body radiation therapy, surgical approaches, and postoperative radiation therapy. Recent results from the ASCENDE-RT trial suggest that brachytherapy boost substantially improves rates of biochemical failure-free survival and PSA nadir < 0.2 ng/mL, but with an increased risk of urinary morbidity. Other studies have suggested that prostatectomy, with potential postoperative radiation therapy based upon pathologic features or rising PSA level, may increase cure rates compared to other treatment options.
In this special issue, we welcome contributions on the subject of local therapy for high-risk prostate cancer. Submissions may address a broad variety of subjects, ranging from technical aspects of local therapies to clinical outcomes, health services research and cost considerations. The aim of this collection is to provide an updated perspective on a range of local therapies for high-risk and very high-risk prostate cancer, including surgical, radiotherapeutic and other approaches. Contributions that focus on regional nodal management, including for node-positive cancers, will also be considered. In addition to an emphasis on original research contributions, we welcome review articles.
We welcome contributions focusing on the following subject areas:
1. PET imaging for staging and target delineation in high-risk prostate cancer
2. Genomics for risk stratification and treatment decisions
3. Therapy approaches including Stereotactic Body Radiation Therapy (SBRT), HDR brachytherapy, combination therapy, and next-generation systemic therapy approaches (e.g. PARPi, Abi/Apa)
4. Neoadjuvant therapy options prior to prostatectomy including radiation therapy, androgen deprivation therapy, and chemotherapy
5. Urologists and Radiation Oncologists perspective on the benefits and drawbacks of prostatectomy for high-risk prostate cancer
6. Optimal timing of postoperative radiation therapy
7. Nodal treatment
Please contact the Guest Editors for discussion of your proposed manuscript prior to submission to avoid duplicative efforts.
